TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15895318

Group type: EXPERIMENTAL
Intervention: Hypoxia (FIO2 = 13% O2) during moderate intensity exercise (80% of FIO2-specific VT)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Hypoxia (FIO2 = 13% O2) during heavy intensity exercise
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Hypoxia (FIO2 = 13% O2) in endurance athletes
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Hypoxia (FIO2 = 13% O2) in sprint trained subjects
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Hypoxia (FIO2 = 13% O2) in untrained controls
Number of subjects: 27

Group type: COMPARATOR
Intervention: Normoxia (FIO2 = 21% O2)
Number of subjects: 27
Study: 12473544

Group type: EXPERIMENTAL
Intervention: Bone marrow-derived progenitor cells
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Circulating blood-derived progenitor cells
Number of subjects: 20

Group type: COMPARATOR
Intervention: Progenitor cells (both types)
Number of subjects: 20
Study: 10389558

Group type: EXPERIMENTAL
Intervention: Diprifusor TCI
Number of subjects: 123

Group type: COMPARATOR
Intervention: MCI
Number of subjects: 123

Group type: COMPARATOR
Intervention: Diprifusor TCI and MCI
Number of subjects: 123
Study: 8897055

Group type: EXPERIMENTAL
Intervention: Scanning laser polarimetry (Nerve Fiber Analyzer type 1, software version 1.6)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Ratios of the measured values
Number of subjects: 56
Study: 1900007

Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 319

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study: 6203024

Group type: EXPERIMENTAL
Intervention: Multimodal therapy (chemotherapy + multiple fractionated radiation therapy)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Multiple daily fractionated radiation therapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Single-modality therapy (chemotherapy alone or radiation therapy alone)
Number of subjects: 58
Study: 30659041

Group type: EXPERIMENTAL
Intervention: TN‐TC11LM (THC:CBD in 1:1 ratio) capsules daily for 12 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: TN‐TC19LM (THC:CBD in 1:9 ratio) capsules daily for 12 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: TN‐TC11LM and TN‐TC19LM capsules
Number of subjects: 26
Study: 29437074

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (self-administered sedation)
Number of subjects: 1
Study: 27798759

Group type: EXPERIMENTAL
Intervention: Baseline soluble ST2 (sST2) levels
Number of subjects: 684

Group type: COMPARATOR
Intervention: Cardiac resynchronization therapy defibrillators (CRT-D)
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Serial assessment of soluble ST2 (sST2)
Number of subjects: 684
Study: 25541552

Group type: EXPERIMENTAL
Intervention: Expressed breast milk (EBM) + Standard practice
Number of subjects: 0
Study: 21745325

Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional rotative instruments
Number of subjects: 36
Study: 20456040

Group type: EXPERIMENTAL
Intervention: L-ornithine-L-aspartate (LOLA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18201764

Group type: EXPERIMENTAL
Intervention: Perifosine 100 mg daily or 900 mg weekly in combination with imatinib
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Topical steroids, topical antibiotics, and lubricating drops
Number of subjects: 5
Study: 16377476

Group type: EXPERIMENTAL
Intervention: Transcranial color Doppler flow imaging (TCDFI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 30
Study: 12554024

Group type: EXPERIMENTAL
Intervention: Squire's Quest! (intervention group)
Number of subjects: 1578

Group type: COMPARATOR
Intervention: Control group (not receiving the program)
Number of subjects: 1578
Study: 10874258

Group type: EXPERIMENTAL
Intervention: Combination of enoxaparin (1 mg/kg) and unfractionated heparin (12,500 IU)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Enoxaparin (1 mg/kg) alone
Number of subjects: 126
Study: 9416718

Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope with in-line stabilization (ILS)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Bullard laryngoscope without ILS
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Bullard laryngoscope with ILS
Number of subjects: 29

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 29
Study: 1587753

Group type: EXPERIMENTAL
Intervention: Stereotactic interstitial brachytherapy with iodine-125 implants
Number of subjects: 68
Study: 3899199

Group type: EXPERIMENTAL
Intervention: fenfluramine
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 30255418

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg BID
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo BID
Number of subjects: 39
Study: 27266221

Group type: EXPERIMENTAL
Intervention: Self-preferred route of delivery (vaginal delivery)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Willingness to perform cesarean delivery on maternal request (CDMR)
Number of subjects: 370
Study: 24881993

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of nebivolol (20 mg/day) and valsartan (320 mg/day)
Number of subjects: 4161

Group type: COMPARATOR
Intervention: Nebivolol (40 mg/day)
Number of subjects: 4161

Group type: COMPARATOR
Intervention: Valsartan (320 mg/day)
Number of subjects: 4161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4161
Study: 22619614

Group type: EXPERIMENTAL
Intervention: Project P.A.T.H.S. Tier 1 Program (experimental group)
Number of subjects: 5934

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 5934
Study: 20721488

Group type: EXPERIMENTAL
Intervention: 80 mg/kg body weight of oral praziquantel divided in two equal doses with 1 h interval (Group 1)
Number of subjects: 288

Group type: COMPARATOR
Intervention: 50 mg/kg body weight of oral praziquantel (Group 2)
Number of subjects: 288
Study: 18398278

Group type: EXPERIMENTAL
Intervention: Remifentanil 4 microg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Alfentanil 40 microg/kg
Number of subjects: 80
Study: 16024518

Group type: COMPARATOR
Intervention: One set at slow speed
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Three sets at high speed
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Three sets at low speed
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: One set at high speed
Number of subjects: 115
Study: 12534505

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (3 injections of 5 U each, total 15 U)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (3 injections of 250 U each, total 750 U)
Number of subjects: 10
Study: 10958578

Group type: EXPERIMENTAL
Intervention: Stressing the personal future consequences of tasks (extrinsic motivation)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 310
Study: 8638792

Group type: EXPERIMENTAL
Intervention: Verapamil 0.1 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Verapamil 0.05 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Diltiazem 0.2 mg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 80
Study: 8186137

Group type: EXPERIMENTAL
Intervention: Terbinafine (250 mg/day)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Itraconazole (100 mg/day)
Number of subjects: 366
Study: 2467488

Group type: EXPERIMENTAL
Intervention: Acitretin 25 mg/day
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acitretin 35 mg/day
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acitretin 45 mg/day
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acitretin 55 mg/day
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acitretin (various dosages)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acitretin (after discontinuation)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acitretin (dosages 45 or 55 mg/day)
Number of subjects: 6
Study: 31149703

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 0
Study: 29072815

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg daily)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 200
Study: 28805667

Group type: EXPERIMENTAL
Intervention: 1.2 g of standardized ginger extract per day
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 27989874

Group type: EXPERIMENTAL
Intervention: Diabetea teaTM (DT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 50
Study: 23336711

Group type: EXPERIMENTAL
Intervention: HYBRID (combined FTP and power training)
Number of subjects: 19

Group type: COMPARATOR
Intervention: FTP (functional task practice)
Number of subjects: 19
Study: 21047840

Group type: EXPERIMENTAL
Intervention: PRP injection
Number of subjects: 54

Group type: COMPARATOR
Intervention: Saline injection (placebo)
Number of subjects: 54
Study: 19880411

Group type: EXPERIMENTAL
Intervention: Ischaemic cardiomyopathy
Number of subjects: 133

Group type: COMPARATOR
Intervention: Non-ischaemic cardiomyopathy
Number of subjects: 133
Study: 17244103

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl patch (Duragesic, 25 microg/h)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 12
Study: 15492435

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied three times a week for 12 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 34
Study: 11505809

Group type: EXPERIMENTAL
Intervention: Combined antibiotic and/or antiphlogistic regimen followed by L-Carnitine 1 g x 2/day + acetyl-Carnitine 0.5 g x 2/day for 3 months (A1/B1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined antibiotic and/or antiphlogistic regimen and L-Carnitine 1 g x 2/day + acetyl-Carnitine 0.5 g x 2/day for 3 months (A2/B2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: L-Carnitine 1 g x 2/day + acetyl-Carnitine 0.5 g x 2/day for 3 months (A3/B3)
Number of subjects: 90
Study: 9561935

Group type: EXPERIMENTAL
Intervention: Immediate treatment (i.t.)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Wait-list control (WL)
Number of subjects: 64
Study: 10163331

Group type: COMPARATOR
Intervention: No treatment (untreated group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with antisecretory or cytoprotective drugs
Number of subjects: 50
Study: 2792164

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Acipimox combined with Cholestyramine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 335771

Group type: EXPERIMENTAL
Intervention: Tilidine 25 mg
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Tilidine 50 mg
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Tilidine 100 mg
Number of subjects: 250

Group type: COMPARATOR
Intervention: Pentazocine 50 mg
Number of subjects: 250
Study: 31802120

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) 2-dose schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) 3-dose schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) 2-dose schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) 3-dose schedule
Number of subjects: 0
Study: 31689771

Group type: EXPERIMENTAL
Intervention: 12-week supervised resistance exercise program combined with home-based aerobic exercise
Number of subjects: 60

Group type: COMPARATOR
Intervention: Home-based aerobic exercise only
Number of subjects: 60
Study: 28333997

Group type: EXPERIMENTAL
Intervention: Variable practice (10 different games)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Repetitive practice (same exergame - ski slalom, twice weekly for 20 minutes over 5 weeks)
Number of subjects: 111
Study: 23915078

Group type: EXPERIMENTAL
Intervention: Real scalpel debridement
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham scalpel debridement
Number of subjects: 80
Study: 19446806

Group type: EXPERIMENTAL
Intervention: e‐SET
Number of subjects: 151

Group type: COMPARATOR
Intervention: DET
Number of subjects: 151
Study: 18923786

Group type: EXPERIMENTAL
Intervention: Sensory-motor-oral stimulation and non-nutritive sucking
Number of subjects: 98

Group type: COMPARATOR
Intervention: Sham stimulation program
Number of subjects: 98
Study: 16361296

Group type: EXPERIMENTAL
Intervention: Ganirelix (0.25 mg/day)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 12566210

Group type: EXPERIMENTAL
Intervention: Nutrition counseling version of TLC
Number of subjects: 190

Group type: COMPARATOR
Intervention: Exercise version of TLC
Number of subjects: 190
Study: 10999263

Group type: EXPERIMENTAL
Intervention: Repeated bouts of maximal voluntary isokinetic eccentric exercise (EX)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 24
Study: 2401028

Group type: EXPERIMENTAL
Intervention: Acupuncture at 6 acupoints of Yang meridian, retained for 30 minutes, daily for 6 weeks.
Number of subjects: 63

Group type: COMPARATOR
Intervention: Calan tablet 5 mg, administered 3 times a day for 6 weeks.
Number of subjects: 63
Study: 7415382

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 0
Study: 30819145

Group type: EXPERIMENTAL
Intervention: Motivational, individual and locally anchored exercise intervention (MILE) including four motivational interviews, six months' free membership to a local sports club, and a GPS-watch/activity monitor.
Number of subjects: 232

Group type: COMPARATOR
Intervention: Routine care including one or two motivational interviews.
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Intervention group (men)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Routine care group (men)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Intervention group (women)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Routine care group (women)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Non-completers
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Completers
Number of subjects: 232
Study: 28163232

Group type: EXPERIMENTAL
Intervention: Target temperature management at 33°C
Number of subjects: 939

Group type: COMPARATOR
Intervention: Target temperature management at 36°C
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Myoclonic seizures
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Status myoclonus
Number of subjects: 939
Study: 26992090

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 95

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Metformin with supplemental insulin
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Metformin (Hr1-GTT >212 mg/dL)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Metformin (Wk1-mFG >95 mg/dL)
Number of subjects: 95
Study: 24162381

Group type: EXPERIMENTAL
Intervention: iceMFP
Number of subjects: 521
Study: 22353811

Group type: EXPERIMENTAL
Intervention: Chemotherapy and thalidomide
Number of subjects: 95

Group type: COMPARATOR
Intervention: Chemotherapy alone (control)
Number of subjects: 95
Study: 20637795

Group type: EXPERIMENTAL
Intervention: Belief-based intervention (three, one hour in-school sessions facilitated by Cancer Council Queensland employees)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control condition (students not receiving the intervention)
Number of subjects: 80
Study: 17420344

Group type: EXPERIMENTAL
Intervention: Copeptin (measured at days 3 to 5)
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Copeptin
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: NTproBNP
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Log copeptin
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Log NTproBNP
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Copeptin above the median (approximately 7 pmol/L) in patients with NTproBNP above the median (approximately 900 pmol/L)
Number of subjects: 980
Study: 16390748

Group type: EXPERIMENTAL
Intervention: LHRH‐A therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 12045509

Group type: COMPARATOR
Intervention: Back school
Number of subjects: 200

Group type: COMPARATOR
Intervention: Joint manipulation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Myofascial therapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Combined joint manipulation and myofascial therapy
Number of subjects: 200
Study: 10825037

Group type: EXPERIMENTAL
Intervention: HA-1A (6 mg/kg of body weight iv; maximum, 100 mg)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study: 8829888

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray
Number of subjects: 59

Group type: COMPARATOR
Intervention: Oral ebastine
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 59
Study: 2704543

Group type: EXPERIMENTAL
Intervention: Vitamin A ointment (all-trans retinoic acid)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 11
Study: 7009819

Group type: EXPERIMENTAL
Intervention: Rifampin (10 mg/kg/dose, 600 mg/dose maximum, twice daily for two days)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 31063019

Group type: EXPERIMENTAL
Intervention: Active recall protocol (phone invitation)
Number of subjects: 96

Group type: COMPARATOR
Intervention: No active recall (no phone invitation)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 96
Study: 28536029

Group type: EXPERIMENTAL
Intervention: CIGB-247 vaccine with adjuvant VSSP, specific anti-VEGF IgG titer diminished but remained above pre-vaccination levels, gradual shift in anti-VEGF IgG response from IgG1 to IgG4, maintained antibodies able to interfere with VEGF/Receptor interaction, production of IFNγ secretion in CD8+ cells.
Number of subjects: 0
Study: 26935748

Group type: EXPERIMENTAL
Intervention: 480 nm optical notch filter
Number of subjects: 48

Group type: COMPARATOR
Intervention: 620 nm sham filter
Number of subjects: 48
Study: 25492271

Group type: EXPERIMENTAL
Intervention: Amlodipine + standard chelation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard chelation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Amlodipine therapy
Number of subjects: 20
Study: 22885164

Group type: EXPERIMENTAL
Intervention: Rituximab chemotherapy induction
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Rituximab chemotherapy induction and 2-year rituximab maintenance
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Rituximab chemotherapy induction and maintenance
Number of subjects: 460
Study: 20580146

Group type: EXPERIMENTAL
Intervention: Immediate lateral expansion technique
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Delayed lateral expansion technique
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 32
Study: 18335394

Group type: EXPERIMENTAL
Intervention: Non-pharmacological intervention for 3 months
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Pharmacological intervention with metformin or acarbose
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 130
Study: 16277712

Group type: EXPERIMENTAL
Intervention: Subcutaneous rHuEPO 40,000 units once per week (group A)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Subcutaneous rHuEPO 40,000 units three times per week (group B)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (intravenous iron saccharate alone)
Number of subjects: 148
Study: 11798992

Group type: EXPERIMENTAL
Intervention: Single-incision technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Two-incision technique
Number of subjects: 20
Study: 10730702

Group type: EXPERIMENTAL
Intervention: Freshman seminar program (small classes with seminar leaders/mentors)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no freshman seminar experience)
Number of subjects: 0
Study: 8646611

Group type: EXPERIMENTAL
Intervention: Low workload condition (model available)
Number of subjects: 45

Group type: COMPARATOR
Intervention: High workload condition (recall without aids)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Dual task condition (secondary task while instructing)
Number of subjects: 45
Study: 2288835

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg) alone
Number of subjects: 9

Group type: COMPARATOR
Intervention: Nifedipine (20 mg) after pretreatment with oral co-trimoxazole
Number of subjects: 9
Study: 6352641

Group type: EXPERIMENTAL
Intervention: Ceftazidime alone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Combination of azlocillin and tobramycin
Number of subjects: 50
Study: 30608620

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0
Study: 28442195

Group type: EXPERIMENTAL
Intervention: Research and Religion
Number of subjects: 129

Group type: COMPARATOR
Intervention: Research Only
Number of subjects: 129

Group type: COMPARATOR
Intervention: Religion Only
Number of subjects: 129
Study: 26509561

Group type: EXPERIMENTAL
Intervention: Study arm II (physician aware of study participation)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Study arm I (physician unaware of study participation)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Participation in study arm II
Number of subjects: 120
Study: 24136801

Group type: EXPERIMENTAL
Intervention: MIS TKA with complete infrapatellar fat pad excision
Number of subjects: 90

Group type: COMPARATOR
Intervention: MIS TKA without infrapatellar fat pad excision
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study: 22516668

Group type: EXPERIMENTAL
Intervention: Clozapine (phase 2E)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untried atypical antipsychotic (phase 2E)
Number of subjects: 0